Breaux Castleman Joins Isis Pharmaceuticals' Board of Directors

       Breaux Castleman Joins Isis Pharmaceuticals' Board of Directors

PR Newswire

CARLSBAD, Calif., June 25, 2013

CARLSBAD, Calif., June 25, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS) announced today that Breaux Castleman has joined the company's
Board of Directors. Mr. Castleman is president and chief executive officer of
Syntiro Healthcare Services, Inc., a health care investment company, which
recently sold its operations as a service provider of integrated care
management and disease management. Mr. Castleman is also a director of USMD
Holdings, Inc. and a senior advisor to McNally Capital LLC in Chicago.

"We are very pleased to have Breaux join our Board. Breaux has held executive
positions in some of the nation's leading managed care provider organizations
and has been a pioneer in creating innovative solutions to deliver value in
the healthcare sector. His successful enterprises in the medical industry
have also provided him with a broad base of experience in delivering medicines
to patients and productively working with payors," said Stanley T. Crooke,
M.D., Ph.D., chairman and chief executive officer of Isis. "Breaux'
leadership and sound business judgment will be valuable to Isis as we continue
to successfully implement our business strategy and evaluate opportunities
within our pipeline to retain some of our drugs to later stages in
development; thereby retaining a larger portion of the commercial upside of
these drugs."

Mr. Castleman also serves as a director of FemPartners, Inc., and a senior
advisor to Match Point Partners LLC in New York. Previously, he held positions
as chairman of Mela Sciences, Inc., director of Med Direct, Inc., president of
the Scripps Clinic, president of Caremark International's Physician Resource
Group, and chief executive officer of the Kelsey-Seybold Clinic. Prior to
that Mr. Castleman was the head of the Houston office of Booz Allen & Hamilton
(now Booz & Co.).

Mr. Castleman received a BA in economics from Yale University and attended New
York University Graduate School of Business Administration. He has published
articles on management issues in business and technical periodicals, including
the Harvard Business Review, and has presented numerous papers and
presentations to industry groups in energy, banking, healthcare, and

Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 28 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, and
cancer. Isis' partner, Genzyme, is commercializing Isis' lead product,
KYNAMRO™, in the United States for the treatment of patients with HoFH.
Genzyme is also pursuing marketing approval of KYNAMRO in other markets.
Isis' patents provide strong and extensive protection for its drugs and
technology. Additional information about Isis is available at

This press release includes forward-looking statements regarding Isis
Pharmaceuticals' business, and the commercial potential of Isis' technologies
and products in development. Any statement describing Isis' goals,
expectations, financial or other projections, intentions or beliefs, including
the commercial potential of KYNAMRO, is a forward-looking statement and should
be considered an at-risk statement. Such statements are subject to certain
risks and uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a business
around such drugs. Isis' forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such forward-looking
statements. Although Isis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on facts and
factors currently known by Isis. As a result, you are cautioned not to rely
on these forward-looking statements. These and other risks concerning Isis'
programs are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31, 2012, and its most recent quarterly
report on Form 10-Q, which are on file with the SEC. Copies of these and other
documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis,"
"Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.
KYNAMRO™ is a trademark of Genzyme Corporation.

SOURCE Isis Pharmaceuticals, Inc.

Contact: D. Wade Walke, Ph.D., Executive Director, Corporate Communications
and Investor Relations, +1-760-603-2741; Amy Blackley, Ph.D., Associate
Director, Corporate Communications, +1-760-603-2772
Press spacebar to pause and continue. Press esc to stop.